



**Date: 06/08/2025**

To,

**National Stock Exchange of India Ltd.**

Exchange Plaza, Bandra Kurla Complex,

Bandra (East), Mumbai- 400 051

**Symbol: MOREPENLAB**

**BSE Limited**

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai- 400 001

**Scrip Code: 500288**

**Subject: Outcome of the meeting of the Board of Directors of the company**

Dear Sir/ Madam,

This is to inform you that the Board of Directors of the company, in their meeting held on Wednesday, 6<sup>th</sup> August 2025 (*commenced at 11.00 a.m. and concluded at 2.30 p.m.*), have, considered and approved, *inter-alia*,:

1. un-audited standalone & consolidated financial results of the company for the quarter ended 30<sup>th</sup> June 2025, based on the recommendation of Audit Committee, in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

The financial results along with the limited review reports of the auditors of the company, are enclosed herewith as **Annexure-A**.

2. record date as Saturday, 30<sup>th</sup> August 2025, for the purpose of determining the members eligible to receive final dividend for the financial year ended 31<sup>st</sup> March 2025, if approved by members at their 40<sup>th</sup> AGM, in accordance with Regulation 42 of Listing Regulations.
3. subject to the approval of members of the company at the forthcoming 40<sup>th</sup> Annual General Meeting ('AGM'), extension of time for hiving off Medical Devices Business, a material related party transaction, into Morepen Medipath Limited (*formerly, Morepen Medtech Limited*), a subsidiary company, as a going concern on slump sale basis.

The information required under the Listing Regulations, as per SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024, was duly submitted on 14<sup>th</sup> January 2025. For brevity, the said details are not reproduced herein.

4. subject to the approval of members at the 40<sup>th</sup> AGM of the company, re-appointment of Mr. Sanjay Suri (DIN:00041590) as Whole-Time Director of the company, pursuant to the recommendation of the Nomination and Remuneration Committee, for a further period of three years with effect from 13<sup>th</sup> August 2025 to 12<sup>th</sup> August 2028 (*both days inclusive*).

### **Morepen Laboratories Limited**

CIN NO. L24231 HP1984PLC006028

**Corp. Off.:** 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA  
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

**Regd. Off.:** Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA  
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

The details as required under the Listing Regulations read with SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024, is given in **Annexure-B**.

5. subject to the approval of members at the 40<sup>th</sup> AGM of the company, appointment of M/s. PD and Associates, proprietorship firm of a practicing Company Secretary, pursuant to the recommendation of the Audit Committee, as Secretarial Auditor, for a term of five (5) consecutive years, commencing from the financial year 2025-26 to financial year 2029-30.

The details as required under the Listing Regulations read with SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024, is given in the **Annexure-C**.

6. the notice of the 40<sup>th</sup> AGM of members of the company, scheduled to be held on Saturday, 6<sup>th</sup> September 2025 through video conferencing / other audio-visual means, in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

You are requested to take the same on record.

Thanking you,

Yours faithfully,

**For Morepen Laboratories Limited**

**Vipul Kumar Srivastava**  
**Company Secretary**  
**F-12148**

**Encl.: a/a.**

## **Morepen Laboratories Limited**

CIN NO. L24231 HP1984PLC006028

**Corp. Off.:** 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA  
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

**Regd. Off.:** Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA  
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

# S.P. Babuta and Associates

Chartered Accountants

#240, Sector 21-A, Chandigarh-160022, Tel: 91 172 2704943, 2713814, Email ID : [spbabuta@hotmail.com](mailto:spbabuta@hotmail.com), Website : [www.babuta.com](http://www.babuta.com)

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF MOREPEN LABORATORIES LIMITED

1. We have reviewed the accompanying statement of consolidated financial results of Morepen Laboratories Limited (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group") for the quarter ended **June 30, 2025** (the "Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the following Group entities:

**Parent:**

Morepen Laboratories Limited

**Indian Subsidiaries :**

- a) Dr. Morepen Limited
- b) Total Care Limited
- c) Morepen Devices Limited



- d) Morepen Rx Ltd.
- e) Morepen Medipath Limited [Formerly Known as Morepen Medtech Limited]
- f) Quick Med Private Limited

**Foreign Subsidiaries :**

- a) Morepen Bio Inc., USA
- b) Morepen Labs FZCO, UAE

Further, Subsequent to the end of the reporting period, the Company's shareholding in Dr. Morepen Limited has come down to 19.94 % from earlier 80%. Accordingly, Dr. Morepen Limited will cease to be a subsidiary and will be accounted for as an investment in subsequent periods.

5. Based on our review conducted and procedures performed as stated in paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of five subsidiaries i.e. Total Care Limited, Morepen Devices Limited, Morepen Rx Ltd., Morepen Bio Inc. and Morepen Labs- FZCO., included in the statement, whose interim financial results reflect total profit/(loss) after tax (before consolidation adjustments) of Rs.5.15 Lakhs (comprising of total revenue of Rs.2203.76 Lakhs and total expenses of Rs.2198.61 Lakhs) and total comprehensive income (before consolidation adjustments) of Rs.5.60 Lakhs for the quarter ended June 30, 2025. The interim financial results of these four subsidiaries except Morepen Labs-FZCO have been reviewed by their auditors whose report has been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these four subsidiaries except Morepen Labs-FZCO, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

The subsidiary, Morepen Bio Inc., is located outside India and its financial information/financial results have been prepared in accordance with accounting principles generally accepted its country and have been reviewed by its auditor under generally accepted auditing standards applicable in its country. The Company's management has converted the interim financial information/financial results of Morepen Bio Inc. from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of Morepen Bio Inc., is based solely on the report of its auditors, the conversion adjustments prepared by the Management of the Company, and reviewed by us, and the procedures performed by us as stated in paragraph 3 above.



# S.P. Babuta and Associates

---

Further, the subsidiary, Morepen Labs–FZCO, is also located outside India, management has confirmed that no operations have commenced in Morepen Labs–FZCO as of the end of reporting period. Accordingly, there is nothing to report in respect of its interim financial information/financial results of Morepen Labs–FZCO. Additionally, No auditors have been appointed for Morepen Labs–FZCO as of the reporting date. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of Morepen Labs–FZCO., is based solely on the Management’s explanation provided to us.

We have not reviewed the financial results of the above-mentioned five subsidiaries, including the foreign subsidiaries, and their financial results are based on management certified financial information.

Our conclusion on the Statement is not modified in respect of the above matters.

**For S.P. Babuta & Associates**  
**Chartered Accountants**  
F. No: 007657N



  
**CA S. P. Babuta**  
Managing Partner  
FCA, IP, DISA, CCA  
GST Cert, Forensic Auditor  
Membership No.: 086348

**Dated: 06/08/2025**  
**Place: Gurugram, Haryana**

**UDIN No.: 25086348 BMIM CH6519**

**Morepen Laboratories Limited**  
**CIN- L24231HP1984PLC006028**  
**Statement of Unaudited Financial Results - Consolidated**  
**For the Quarter Ended June 30, 2025**

(Rs.in Lakhs, except per share data)

Sl.	Particulars	Quarter Ended		Year Ended	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	<b>Income</b>				
	Income from operations (Net)	42523.88	46585.33	45521.57	181157.58
	Other Income	440.85	461.14	342.70	1836.37
	<b>Total Income</b>	<b>42964.73</b>	<b>47046.47</b>	<b>45864.27</b>	<b>182993.95</b>
2.	<b>Expenditure</b>				
	a) Cost of Material Consumed	23770.89	26842.90	23501.46	99918.31
	b) Purchase of stock - in - trade	1703.99	7130.71	5597.43	20724.66
	c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade	761.59	(2398.39)	(817.75)	(4712.25)
	d) Employee Benefits Expenses	5523.67	5700.73	4795.52	20891.39
	e) Finance Cost	403.78	467.16	115.19	834.29
	f) Depreciation and Amortization	902.51	1646.79	572.78	2898.17
	g) Power and Fuel	1055.80	1206.61	927.23	4062.30
	h) Travelling Expenses	618.91	760.18	544.07	2526.30
	i) Selling and Distribution Expenses	3039.64	488.64	2958.03	7998.63
	j) Other Expenses	3632.31	2629.67	2853.70	12341.21
	<b>Total Expenditure</b>	<b>41413.09</b>	<b>44475.00</b>	<b>41047.66</b>	<b>167483.01</b>
3.	<b>Profit before Tax (1-2)</b>	<b>1551.64</b>	<b>2571.47</b>	<b>4816.61</b>	<b>15510.94</b>
4.	<b>Tax Expense</b>				
	Current Tax	378.12	67.72	1199.82	3236.69
	Earlier Periods Tax	32.86	-	-	-
	Deferred Tax	-	472.71	-	472.71
	<b>Total Tax</b>	<b>410.98</b>	<b>540.43</b>	<b>1199.82</b>	<b>3709.40</b>
5.	<b>Net Profit for the period/Year (3-4)</b>	<b>1140.66</b>	<b>2031.04</b>	<b>3616.79</b>	<b>11801.54</b>
6.	Share of Minority Interest in (Profit)/Loss	65.83	(0.50)	-	(0.50)
7.	Net Profit after Minority Interest (5-6)	<b>1074.83</b>	<b>2031.54</b>	<b>3616.79</b>	<b>11802.04</b>
8.	<b>Other Comprehensive Income/ (Loss) (OCI)</b>				
	Items that will not be reclassified to Profit & Loss	79.05	(112.61)	343.06	25.05
	Income Tax	20.05	(27.40)	85.91	5.80
	Exchange differences on translation of foreign operations	-	4.87	-	6.12
	<b>Other Comprehensive Income/ (Loss) (Net of Tax)</b>	<b>59.00</b>	<b>(80.34)</b>	<b>257.15</b>	<b>25.37</b>
9.	<b>Total Comprehensive Income (7+8)</b>	<b>1133.83</b>	<b>1951.20</b>	<b>3873.94</b>	<b>11827.41</b>
10.	<b>Paid-up Equity Share Capital of Face Value of Rs.2/- each</b>	10958.41	10958.41	10222.71	10958.41
11.	<b>Other Equity</b>				104664.66
12.	<b>Earning Per Share (in Rs.)</b>				
	- Basic	0.20	0.35	0.71	2.20
	- Diluted	0.20	0.35	0.71	2.20

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 06, 2025. A Limited review of the same has been carried out by the Statutory Auditors.
- The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended December 31, 2024. The consolidated financial results includes the financials of the Company and its subsidiaries as listed in Annexure 1, except Morepen Labs-FZCO incorporated during the quarter as a wholly owned subsidiary, which is yet to start its operations.
- Pursuant to the sale of 1.53 Crore equity shares of Dr. Morepen Limited (DML) for Rs.30.65 Crore and further fresh issue of 7.64 crore equity shares by DML to the shareholders of Groom Town Private Limited (GTPL) for acquiring 100% equity shares of GTPL for Rs.153.01 Crore, the company's shareholding in DML has come down from 80% to 19.94%.
- The Company is engaged only one operating segment namely, Pharmaceuticals.

Place : Gurugram, Haryana

Date : August 06, 2025

For and on behalf of the Board of Directors



(Sushil Suri)

Chairman & Managing Director

Annexure - 1

List of entities included in the Consolidated Financial Results :

Sr.No.	Name of the Entity	Status	% holding	Held by
1	Morepen Laboratories Ltd.	Holding Company	Parent Co.	Parent Company
2	Morepen Rx Ltd.	Wholly Owned Subsidiary	100%	Morepen Laboratories Ltd.
3	Morepen Devices Ltd.	Wholly Owned Subsidiary	100%	Morepen Laboratories Ltd.
4	Morepen Bio Inc., USA	Wholly Owned Subsidiary	100%	Morepen Laboratories Ltd.
5	Dr. Morepen Ltd.	Subsidiary	80%	Morepen Laboratories Ltd.
6	Morepen Medipath Limited ( Formerly Morepen MedTech Limited)	Subsidiary	60%	Morepen Laboratories Ltd.
7	Total Care Ltd.	Subsidiary	95%	Dr. Morepen Ltd.
8	Quick Med Private Limited	Subsidiary	80%	Dr. Morepen Ltd.



# S.P. Babuta and Associates

Chartered Accountants

#240, Sector 21-A, Chandigarh-160022, Tel: 91 172 2704943, 2713814, Email ID: [spbabuta@hotmail.com](mailto:spbabuta@hotmail.com), Website: [www.babuta.com](http://www.babuta.com)

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### TO THE BOARD OF DIRECTORS OF MOREPEN LABORATORIES LIMITED

1. We have reviewed the accompanying statement of standalone financial results of Morepen Laboratories Limited (the "Company") for the quarter **ended June 30, 2025** (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. Subsequent to the end of the reporting period, the Company's shareholding in Dr. Morepen Limited has come down to 19.94 % from earlier 80%. Accordingly, in the standalone financial statements, the investment will be reclassified from "Investment in Subsidiary" to "Other Investments" in subsequent periods, in line with the applicable Indian Accounting Standards.



Our conclusion on the Statement is not modified in respect of the above matter.

**For S.P. Babuta & Associates**  
**Chartered Accountants**  
F. No: 007657N



*S.P. Babuta*  
**CA S. P. Babuta**  
Managing Partner  
FCA, IP, DISA, CCA  
GST Cert, Forensic Auditor  
Membership No.: 086348

**Dated: 06/08/2025**  
**Place: Gurugram, Haryana**

**UDIN No.:** 25086348BMIMCG5180

**Morepen Laboratories Limited**  
CIN- L24231HP1984PLC006028  
**Statement of Unaudited Financial Results - Standalone**  
**For the Quarter Ended June 30, 2025**

(Rs.in Lakhs, except per share data)

Sl.	Particulars	Quarter Ended		Year Ended	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1.	<b>Income</b>				
	Income from operations (Net)	39128.43	38193.77	38564.32	155453.53
	Other Income	409.23	314.24	307.19	1571.96
	<b>Total Income</b>	<b>39537.66</b>	<b>38508.01</b>	<b>38871.51</b>	<b>157025.49</b>
2.	<b>Expenditure</b>				
	a) Cost of Material Consumed	23770.89	26842.90	23501.46	99918.31
	b) Purchase of stock - in - trade	130.73	576.64	580.68	2081.11
	c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade	982.96	(2145.99)	(922.03)	(4436.05)
	d) Employee Benefits Expenses	4668.84	4814.76	3993.54	17722.43
	e) Finance Cost	381.16	374.29	104.42	710.29
	f) Depreciation and Amortization	787.92	1225.42	359.02	2444.21
	g) Power and Fuel	1055.75	1206.55	927.23	4062.24
	h) Travelling Expenses	426.17	576.25	370.87	1832.74
	i) Selling and Distribution Expenses	2626.56	542.82	2615.92	7000.01
	j) Other Expenses	3571.40	2763.93	2635.62	11931.64
	<b>Total Expenditure</b>	<b>38402.38</b>	<b>36777.57</b>	<b>34166.73</b>	<b>143266.93</b>
3.	<b>Profit before tax (1-2)</b>	<b>1135.28</b>	<b>1730.44</b>	<b>4704.78</b>	<b>13758.56</b>
4.	<b>Tax Expense</b>				
	Current Tax	296.30	66.59	1199.82	3128.33
	Earlier Periods Tax	32.86	-	-	-
	Deferred Tax	-	472.71	-	472.71
	<b>Total Tax</b>	<b>329.16</b>	<b>539.30</b>	<b>1199.82</b>	<b>3601.04</b>
5.	<b>Net Profit for the period/Year (3-4)</b>	<b>806.12</b>	<b>1191.14</b>	<b>3504.96</b>	<b>10157.52</b>
6.	<b>Other Comprehensive Income (OCI)</b>				
	Items that will not be reclassified to Profit & Loss	76.82	(107.12)	341.46	23.03
	Income Tax	20.05	(27.40)	85.91	5.80
	<b>Other Comprehensive Income (Net of Tax)</b>	<b>56.77</b>	<b>(79.72)</b>	<b>255.55</b>	<b>17.23</b>
7.	<b>Total Comprehensive Income (5+6)</b>	<b>862.89</b>	<b>1111.42</b>	<b>3760.51</b>	<b>10174.75</b>
8.	<b>Paid-up Equity Share Capital of Face Value of Rs.2/- each</b>	10958.41	10958.41	10222.71	10958.41
9.	<b>Other Equity</b>				107191.81
10.	<b>Earning Per Share (in Rs.)</b>				
	- Basic EPS	0.15	0.20	0.69	1.90
	- Diluted EPS	0.15	0.20	0.69	1.90

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on August 06, 2025. A Limited review of the same has been carried out by the Statutory Auditors.
- The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended December 31, 2024.
- Pursuant to the sale of 1.53 Crore equity shares of Dr. Morepen Limited (DML) for Rs.30.65 Crore and further fresh issue of 7.64 crore equity shares by DML to the shareholders of Groom Town Private Limited (GTPL) for acquiring 100% equity shares of GTPL for Rs.153.01 Crore, the company's shareholding in DML has come down from 80% to 19.94%.
- The Company is engaged only one operating segment namely, Pharmaceuticals.

For and on behalf of the Board of Directors

Place : Gurugram, Haryana  
Date : August 06, 2025



(Sushil Suri)  
Chairman & Managing Director

**Annexure - B**

**Disclosure in terms of Regulation 30 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024**

S. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Re-appointment of Mr. Sanjay Suri as Whole-Time Director on account of the completion of tenure of three years on 12 <sup>th</sup> August 2025.
2.	Date of Appointment/ reappointment/ cessation (as applicable) and terms of appointment /reappointment;	<b>Date of re-appointment:</b> 6 <sup>th</sup> August 2025  <b>Term of re-appointment</b> Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Sanjay Suri as Whole-Time Director for a further period of three (3) years with effect from 13 <sup>th</sup> August 2025 to 12 <sup>th</sup> August 2028 ( <i>both days inclusive</i> ), subject to the approval of members at the 40 <sup>th</sup> AGM of the Company.
3.	Brief Profile (in case of appointment)	Mr. Sanjay Suri is a Bachelor of Science (B.Sc.), having more than thirty years of experience in pharmaceuticals industry.  He has varied experience in the field of international sales and marketing, joint ventures, statutory and regulatory approvals (including USFDA), strategic planning, manufacturing operations, including finance, accounts and banking.
4.	Disclosure of relationship between directors (in case of appointment of a director).	Mr. Sanjay Suri is a member of promoter group of the company and brother of Mr. Sushil Suri, Chairman and Managing Director & Promoter of the company.
5.	Other information	He is not debarred from holding the office of Director by virtue of any order passed by the SEBI or any other such authority.

**Morepen Laboratories Limited**

CIN NO. L24231 HP1984PLC006028

**Corp. Off.:** 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA  
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

**Regd. Off.:** Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA  
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com

### Annexure - C

**Disclosure in terms of Regulation 30 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November 2024**

S. No.	Particulars	Details
1.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of M/s. PD and Associates, Company Secretaries, as Secretarial Auditor of the Company.
2.	Date of Appointment/ reappointment/ cessation (as applicable) and terms of appointment /reappointment;	<b>Date of appointment:</b> 6 <sup>th</sup> August 2025 <b>Term of appointment:</b> Act as a Secretarial Auditor for a term of five (5) consecutive years, commencing from the financial year 2025-26 to financial year 2029-30, subject to the approval of the members at the 40 <sup>th</sup> AGM of the company.
3.	Brief Profile (in case of appointment)	M/s. PD and Associates, Company Secretaries, is a peer-reviewed proprietorship firm represented by FCS Praveen Dua, registered with the Institute of Company Secretaries of India and having extensive experience of over thirty one (31) years. The expertise of the firm spans over various areas such as due diligence, merger & acquisition, advisory and consulting, joint venture and representation services.
4.	Disclosure of relationship between directors (in case of appointment of a director).	Not Applicable

#### Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

**Corp. Off.:** 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA  
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

**Regd. Off.:** Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA  
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com